Table 7.
Relevant pharmacogenetics association studies that focused on serotonin receptor 1A (5HT1A)
| Reference | Gene | Drug | Sample | Outcome measure | Results | p-value |
|---|---|---|---|---|---|---|
| [44] | 5HT1A | SSRIs | 133 depressed patients | HAMD | No association | Not significant |
| [46] | 5HT1A | Citalopram | 130 depressed patients | HAMD | No association | p = 0.009 |
| [88] | HTR1A | Fluvoxamine | 151 major depressed and 111 bipolar patients | HAMD | C/C genotype (C(-1019)G) carriers showed a better response to fluvoxamine | p = 0.036 |
| [48] | 5HT1A | Fluoxetine | 96 subjects with unipolar major depression | HAMD | No association | Not significant |
| [89] | HTR1A | Fluoxetine | 222 major depressed patients | HAMD | Patients with -1019C/C genotype associated with better response | p = 0.001 (females) p = 0.007 (males) |
| [65] | HTR1A | Fluoxetine | 224 major depressed patients | HAMD | HTRIA -1019C/C was found to be associated with a better response | p = 0.009 |
| [20] | HTR1A | Fluvoxamine | 100 depressed outpatients | HAMD | No association | Not significant |
Abbreviations: SSRI, selective serotonin reuptake inhibitor; HAMD, Hamilton Rating Scale for Depression; 5HT1A and HTR1A, serotonin receptor 1A